Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:approves |
gptkb:2009
gptkb:FDA |
gptkbp:availability |
prescription only
|
gptkbp:brand |
gptkb:Sabril
|
gptkbp:category |
gptkb:C
|
gptkbp:class |
gptkb:Antihero
|
gptkbp:clinical_trial |
epilepsy treatment study
|
gptkbp:clinical_use |
long-term management of epilepsy
short-term treatment of infantile spasms |
gptkbp:contraindication |
severe renal impairment
concurrent use of certain medications hypersensitivity to vigabatrin |
gptkbp:counseling_services |
importance of adherence to therapy
reporting any mood changes risk of vision loss |
gptkbp:dosage_form |
oral
|
gptkbp:formulation |
gptkb:tablet
powder for oral solution |
https://www.w3.org/2000/01/rdf-schema#label |
Sabril
|
gptkbp:indication |
infantile spasms
|
gptkbp:ingredients |
vigabatrin
|
gptkbp:interacts_with |
gptkb:beer
other CNS depressants other antiepileptic drugs |
gptkbp:is_monitored_by |
gptkb:weight
kidney function vision tests |
gptkbp:manufacturer |
gptkb:Lundbeck
|
gptkbp:marketed_as |
gptkb:Sabril
|
gptkbp:mechanism_of_action |
inhibits GABA transaminase
|
gptkbp:packaging |
gptkb:bottle
blister pack |
gptkbp:patient_population |
gptkb:children
adults infants |
gptkbp:pharmacokinetics |
excreted in urine
not extensively metabolized half-life of 5 to 9 hours |
gptkbp:research |
investigations into long-term effects
ongoing studies on efficacy in different populations studies on combination therapy with other anticonvulsants |
gptkbp:route_of_administration |
oral
|
gptkbp:safety |
not recommended for use in pregnancy unless necessary
monitoring required during treatment risk of permanent vision loss not recommended for use in breastfeeding without consulting a doctor |
gptkbp:side_effect |
gptkb:depression
fatigue irritability drowsiness weight gain peripheral neuropathy vision loss somnolence |
gptkbp:storage |
room temperature
|
gptkbp:used_for |
treating epilepsy
|
gptkbp:bfsParent |
gptkb:Lundbeck
|
gptkbp:bfsLayer |
6
|